O12 Giant cell arteritis in Mumbai. A study of 16 cases

Singh, Shipra; Balakrishnan, C.; Mangat, G; Samant, Rohan; Bambani, M.; Kalke, Shubhada; Vr, Joshi

doi:10.1016/s0973-3698(10)60229-4

Cited by 7 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, it has been estimated that the rate of GCA in people of Asian ethnicity is approximately 20 times less common than their Caucasian counterparts (27,28). There are also reports of GCA in people of Indian descent (29) (30).…”

Section: Discussionmentioning

confidence: 99%

Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050

Smit

Palmer²,

Hewitt³

2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050

Smit

Palmer²,

Hewitt³

2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Significantly lower incidences have been reported from Turkey (1.13 per 100,000 people ≥50 years) [40] and Japan (1.47 per 100,000 ≥50 years) [41]. Case reports have been published from Mumbai, India [42] and Riyadh, Saudi Arabia [43], Tunisia [44].…”

Section: Other Reportsmentioning

confidence: 99%

Update on the Epidemiology and Treatment of Giant Cell Arteritis

Koster

Warrington

Kermani

2016

Curr Treat Options in Rheum

View full text Add to dashboard Cite

Opinion statementGiant cell arteritis is the most common form of primary systemic vasculitis in people over the age of 50 years. This disease affects the aorta and its branches, and complications may include vision loss, arterial stenosis, and aortic aneurysm. Early recognition and treatment of giant cell arteritis is important to mitigate long-term damage. While glucocorticoids remain the mainstay of treatment, relapses are common and morbidity related to treatment frequently occurs. There is an unmet need for immunosuppressive therapies that are able to induce long-term remission while avoiding the adverse effects of glucocorticoids. Of available conventional immunosuppressive treatments, methotrexate is generally considered a first-line steroid-sparing agent for patients with disease refractory to glucocorticoids and in those at high risk for glucocorticoid-associated toxicity. Advances in understanding of disease pathogenesis continue to identify potential therapeutic targets, and several biologic agents are currently under investigation. Preliminary reports from controlled studies demonstrate potential efficacy of tocilizumab and abatacept in both newly diagnosed and relapsing patients; however, use of these agents should not yet be considered standard therapy. The role of anti-platelet therapy in prevention of ischemic complications is controversial, but low-dose aspirin is considered reasonable in this population. Statin medications have little role in the management of giant cell arteritis (GCA) and should be reserved for those with clinical indications for lipid reduction. Correction of arterial stenosis with surgical revascularization is uncommonly required for patients with refractory ischemic symptoms. Intervention should be performed in patients with quiescent disease. Monitoring for late-onset complications, particularly thoracic aortic aneurysm, should take place though the frequency of screening and the optimal timing of intervention is not established. AgeGCA almost never occurs in individuals below the age of 50 years [11]. In a systematic literature review, only 2 out of 1435 subjects (0.1 %) from 26 studies were younger than 50 years of age [11]. In most studies, the mean age at diagnosis of GCA is in the eighth decade of life [10]. Further strengthening the association between age and risk of GCA are several studies where the incidence of GCA Epidemiology and Treatment of Giant Cell Arteritis Koster et al.

show abstract

“…Therefore, there is also little information on the clinical picture of GCA in Asian countries, although a number of relatively small case series have been reported from Japan, China and India . These reports are summarized in Table , and are compared to Australian Caucasian GCA patients .…”

Section: Epidemiologymentioning

confidence: 99%

Diagnosis and management of giant cell arteritis: an Asia‐Pacific perspective

2018

View full text Add to dashboard Cite

Giant cell arteritis is the commonest primary vasculitis of the elderly. However, the prevalence does vary widely between populations with highest incidence amongst Northern Europeans and lowest amongst East Asians. Preliminary studies suggest that clinical manifestations may differ between different populations. Newer diagnostic approaches including ultrasound, MR angiography and PET imaging are under review. While there have been recent advances in the diagnosis of GCA particularly with regard to imaging, there is an urgent need for improvements in methods of diagnosis, treatment and requirement for screening. Glucocorticoid treatment remain the backbone of therapy. However, glucocorticoid therapy is associated with significant adverse effects. Conventional and novel immunosuppressive agents have only demonstrated modest effects in a subgroup of steroid refractory GCA due to the different arms of the immune system at play. However, recently a study of IL-6 blockade demonstrated benefit in GCA. Newer approaches such as fast-track pathways can also result in improvements in consequences of GCA including blindness.

show abstract

O12 Giant cell arteritis in Mumbai. A study of 16 cases

Cited by 7 publications

References 0 publications

Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050

Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050

Update on the Epidemiology and Treatment of Giant Cell Arteritis

Diagnosis and management of giant cell arteritis: an Asia‐Pacific perspective

Contact Info

Product

Resources

About